Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
International Journal of Molecular Sciences|August 6, 2020
P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative DiseaseUrsula A Germann, John J AlamBiochemical Pharmacology|February 6, 2004
Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytesJugnu Jain, Susan J Almquist, Pamella J Ford, et al.Proceedings of the National Academy of Sciences of the United States of America|October 21, 2003
Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiationYao Yao, Wei Li, Junwei Wu, et al.The Journal of Pharmacology and Experimental Therapeutics|February 10, 2007
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18Woods Wannamaker, Robert Davies, Mark Namchuk, et al.Antimicrobial Agents and Chemotherapy|July 15, 2015
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 InhibitorsAlice W Tsai, Colleen F McNeil, Joshua R Leeman, et al.Journal of Medicinal Chemistry|February 16, 2007
Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitorsAlex M Aronov, Christopher Baker, Guy W Bemis, et al.Molecular Cancer Therapeutics|September 24, 2017
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)Ursula A Germann, Brinley F Furey, William Markland, et al.Journal of Medicinal Chemistry|October 16, 2009
Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational controlAlex M Aronov, Qing Tang, Gabriel Martinez-Botella, et al.ACS Medicinal Chemistry Letters|June 6, 2014
The Discovery of VX-745: A Novel and Selective p38α Kinase InhibitorJohn P Duffy, Edmund M Harrington, Francesco G Salituro, et al.Journal of Medicinal Chemistry|December 18, 2009
Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindoleTiansheng Wang, John P Duffy, Jian Wang, et al.Pageof 2